Janssen Strikes US$3.75 B RNAi Partnership with Arrowhead

By Michelle Liu

Pharma Deals Review: Vol 2018 Issue 10 (Table of Contents)

Published: 13 Oct-2018

DOI: 10.3833/pdr.v2018.i10.2363     ISSN: 1756-7874

Section: Licensing



Following the discontinuation of its EX1 drug delivery platform, Arrowhead Pharmaceuticals has come back with its Targeted RNAi Molecule (TRiM™) technology and signed a two-part deal with Janssen Pharmaceuticals worth potentially US$3...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details